UpdatesPress Release
Jubilant Pharmova's Q1 FY27 revenue grew 17% to Rs 2,229 Cr.
Jubilant Pharmova LimitedJUBLPHARMA · Filed with the exchange
EBITDA fell 11% to Rs 268 Cr due to SPECT product issues & Montreal costs.
SPECT production resumes; H2 FY27 recovery expected.
CDMO Line 3 ramps up, Line 4 installed, US$60M+ PET expansion underway.
No comments yet. Be the first.